RB to be an important player in directing the choice between permanent arrest and apoptosis. T h e antagonism between RB and c-Abl/p73 may modulate the function of p53 to direct the choice between growth arrest and apoptosis in DNA damaged cells.
Growth arrest and apoptosis are diKerentiation-coupled cell fates
Regulated cell proliferation is an important aspect of homeostasis in multi-cellular organisms. Cell proliferation is required to renew tissues, to repair woundsand to fight infections. In each of these processes, proliferation is directed at producing cells with specialized functions. Therefore, normal cell proliferation is coupled with differentiation. Terminally differentiated cells cease to proliferate and then adopt one of two fates, either to survive in an arrested state or to undergo programmed cell death (apoptosis) (Figure 1 ). T h e choice between growth arrest and apoptosis is determined b y the differentiation programme. In tissues with constant renewal, such as the skin, terminally differentiated cells are programmed to undergo apoptosis. In tissues that require the long-term survival of terminally differentiated cells, such as neurons or cardiac myocytes, differentiation is coupled with terminal growth arrest. Thus, the
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Growth arrest and apoptosis are induced by genotoxic stress
T h e fate of growth arrest or apoptosis can also be activated by genotoxic stress (Figure 1 ). T h e primary cellular response to genotoxic stress is the activation of checkpoints to arrest the cell cycle. Genotoxic stress can also induce a sustained arrest that resembles senescence, which can be distinguished from the cell-cycle checkpoints (Figure 1) .
Mechanistically, cell-cycle checkpoints are signalling pathways composed of protein kinases [1, 2] . DNA damage signals are transduced by a cascade of protein phosphorylation events, leading to the inhibition of DNA replication and mitosis (Figure 2 ). T h e checkpoint pathways are activated by the kinases encoded by the A T M (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia-related) genes in mammalian cells. A T M and ATR can activate the kinases hChkl and hCdsl ( Figure 2) . hChkl activates the G, checkpoint by phosphorylating the dual-specificity phosphatase Cdc25C to inhibit its function [3-51.
T h e Cdc25C activity is required to dephosphorylate and activate the cyclin B-Cdc2 kinase complex, which functions as the M-phase promoting factor (MPF) to stimulate the entry into M-phase [ 6 ] .
T h e inhibition of Cdc25C prevents the activation of MPF, thus causing a damaged cell to arrest in G, phase of the cell cycle. hCds1 phosphorylates the dual specificity phosphatase Cdc25A to promote its degradation [7] . Cdc25A activity is required to dephosphorylate and activate the cyclin A-Cdk2 kinase complex, which functions as the Sphase promoting factor (SPF). T h e degradation of Cdc25A prevents the activation of cyclin A-Cdk2, thereby causing a damaged cell to stop DNA replication.
These kinase-dependent cycle checkpoints are activated rapidly following DNA damage. Because protein phosphorylation is reversible,
Cell-cycle checkpoint kinase cascades
In mammalian cells, the kinases ATR and ATM can be activated by genotoxic stress. ATR and ATM can then activate signalling pathways to prevent either the entry into mitosis (G, checkpoint) or the continued replication of DNA (S Checkpoint). The G, checkpoint pathway requires the kinase hChk I, which phosphorylates Cdc25C to inhibit its function in activating MPF (which is the kinase for the cyclin ECdc2 complex). The S checkpoint pathway is mediated by hCds I, which phosphorylates Cdc25A. causing its degradation. Because Cdc25A is an activator of SPF (the kinase for the cyclin A-Cdk2 or E-Cdk2 complexes), the degradation of Cdc25A causes the inhibition of DNA replication. In DNA damage response, the choice between growth arrest and apoptosis is determined by the extent of damage, and by the developmental lineage of a cell. With cultured fibroblasts, premature senescence or apoptosis is induced after exposure to a high dose of DNA damage inducers. This and other observations suggest that irreparable DNA damage rnay be an important signal in the activation of permanent growth arrest or apoptosis. With lymphocytes and epithelial cells, DNA damage readily activates apoptosis, even at relatively low dose of damage inducers. During neuronal development, the undifferentiated neuroblasts readily undergo apoptosis following ionizing radiation at doses that do not cause the death of mature neurons. T h e different apoptosis responses to DNA damage of different cell types could be due to two possible reasons. First, lymphocytes, epithelial cells and neuroblasts may have a lower repair capacity so that they are more sensitive to damage-induced apoptosis. Alternatively, the decision to undergo apoptosis rnay not be determined simply by DNA repair but can also be affected by the differentiation program. Taken together, the current observations suggest that a multitude of factors can affect a cell's decision to undergo growth arrest or apoptosis after DNA damage.
Induction of growth arrest and apoptosis by genotoxic stress is dependent on p53
T h e p53 protein is a transcription factor that is frequently mutated in human cancer. DNA damage can activate p53 through the checkpoint kinases to cause cell-cycle arrest or apoptosis ( Figure 3 ). T h e p53-dependent G,-arrest is mediated by the transcription upregulation of p21 Cipl [8-lo] . T h e heat-stable p21Cipl protein is a stoichiometric inhibitor of the cyclin E-Cdk2 and cyclin A-Cdk2 complexes, which are activators of DNA synthesis [ l l ] . Increased expression of 0 2001 Biochemical Society p21 Cipl can therefore inhibit S-phase entry, contributing to a cell-cycle arrest in G,. T h e p53-dependent G, arrest is mediated by the transcriptional upregulation of 14-3-30 [ 121. This adaptor protein binds to and retains the cyclin B-Cdc2 complex in the cytoplasm. T h e cyclin B-Cdc2 kinase complex must function in the nucleus to initiate mitosis [13] . Thus, the cytoplasmic retention of cyclin B-Cdc2 can inhibit M-phase entry, contributing to cell-cycle arrest in G,. T h e p53-dependent G, arrest is mechanistically distinct from the G, checkpoint that is activated by the kinase cascade ( Figure 2 ). Because p53-dependent cell-cycle arrests require de no00 synthesis of p21Cipl and 14-3-3a mRNA and proteins, they are slower in onset than the cellcycle checkpoints that are regulated by the kinase cascade. DNA damage can also activate p53 to cause apoptosis [14] . In Drosophilu, DNA damage can activate the fly p53 protein to upregulate the
mR-3 p53-dependent cell-cycle arrest pathways
In mammalian cells, the kinases ATR ATM. hChk I and hCds I can also activate p53 function in response to genotoxic stress. Despite the understanding of how p53 activates growth arrest and apoptosis, the rules that govern these two mutually exclusive functions of p53 are not known. There are two possible mechanisms for the regulation of p53-dependent growth arrest and apoptosis. T h e first mechanism is to modify p53 itself; for example, the p53 protein that activates the transcription of p21Cipl may be modified differently from the p53 that activates the transcription of Bax. T h e second mechanism is to modify co-factors that can restrict the function of p53. These two mechanisms are not mutually exclusive. This discussion will be focused on the second mechanism, i.e. that other proteins help to determine whether p53 induces either growth arrest or apoptosis. We propose that the p53-dependent growth arrest requires the retinoblastoma tumour suppressor protein (RB), whereas p53-dependent apoptosis requires the inactivation of RB. In other words, we propose that RB has two functions: it inhibits proliferation and apoptosis. In DNA damage response, RB functions as a downstream efiector in p53-and p21Cipl-dependent growth arrest. In addition, RB functions as an inhibitor of apoptosis, by inhibiting the apoptosis function of c-Abl and p73. Thus, the antagonism between RB and c-Abl/p73 can contribute to the choice of growth arrest or apoptosis in damaged cells.
RB inhibits cell proliferation and apoptosis
RB is an inhibitor of cell proliferation [16] : it can assemble transcription repression complexes to inhibit the expression of genes that are regulated by the transcription factor E2F [17] . T h e promoters of cyclin E, cyclin A and Cdc2 contain EZF-binding sites [18, 19] . Active RB is recruited to these promoters by binding to E2F. RB further recruits chromatin-modifying enzymes, such as the Brg complex or the histone deacetylases, to mediate transcription repression [20, 21] . Cyclin E, cyclin A and Cdc2 are essential components of the cell-cycle engine. By repressing the expression of these genes, RB can block cell proliferation.
T h e expression of RB is upregulated during muscle differentiation [22] . T h e myogenic transcription factors also upregulate p21 Cipl, which can initiate cell-cycle arrest by inhibiting the cyclin-dependent protein kinases [23] . However, the upregulation of p21Cipl is not sufficient to cause terminal growth arrest of differentiated muscle cells. T h e permanent growth arrest, which cannot be reversed by mitogenic stimulation, requires RB [24, 25] . In the absence of RB, myogenic differentiation is uncoupled from terminal growth arrest. Consequently, RB-deficient myoblasts undergo apoptosis [26, 27] . Neuroblasts in RB-deficient mice also die during embryonic development [28-301. These results demonstrate a critical role for RB in the establishment of longterm survival during differentiation.
RB is also activated by genotoxic stress, and it plays an essential role in p53-dependent growth arrest [31-331. RB is inactivated by phosphorylation in late GI-, S-, G,-and M-phases of the cell cycle [16, 34] . T h e phosphorylation of RB is catalysed by the cyclin-dependent protein kinases. Because of Cdk inhibition by p21Cip1, the phosphorylation of RB is inhibited in damaged cells. In early GI cells that contain the hypophosphorylated RB, inhibition of Cdk activity has the immediate effect of G,-arrest by maintaining RB in the active state. Indeed, RB is required for DNA damage to cause G I arrest, as RB-deficient cells are defective in the G,-arrest response to DNA damage [31-331. In S-, G,-and M-phase cells, the inhibition of Cdk activity causes the newly synthesized RB to accumulate in a hypophosphorylated form, which can repress gene expression. With the repression of cyclin A expression, DNA replication can be blocked. Indeed, dephosphorylation of RB was observed in S-phase cells following cisplatin treatment, and this led to a prolonged arrest of damaged cells with S-phase DNA content [33] . T h e arrest in S-phase was not observed with RB-deficient cells. Dephosphorylation of RB was also observed in G, cells following a high dose of ionizing radiation, leading to a prolonged arrest of damaged cells with G, DNA content (S. Naderi and J, Y. J. Wang, unpublished data). Again, this prolonged G, arrest was not observed with RB-deficient cells. Taken together, these results show that RB is an important downstream effector in the p53/p21 Cipl pathway, and RB can arrest damaged cells in the G,-, S-or G,-phases of the cell cycle.
RB-deficient cells that are unable to adopt the fate of growth arrest are susceptible to apoptosis. T h e negative correlation between growth arrest and apoptosis in DNA damage response has been widely reported. In parallel, a positive correlation between proliferation and apoptosis is also observed, particularly with oncogene-stimulated proliferation [35] . T h e coupling of DNA synthesis and apoptosis is best illustrated by the ability of E2F-1 to activate DNA synthesis as well as apoptosis [36] . T h e ectopic expression of E2F-1 can drive cells into S-phase in the absence of exogenous growth factors. However, without the survival signals provided by the growth factors, E2F-1 also causes apoptosis [36] . RB can inhibit both the S-phase-and apoptosis-promoting functions of E2F. Thus, RB can promote growth arrest and inhibit apoptosis. Because the inactivation of RB during cell-cycle progression can stimulate both DNA synthesis and apoptosis, cell proliferation is strongly dependent on survival signals to 
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block the apoptosis pathway that is inhibited by RB.
T h e apoptosis promoting function of E2F-1 is dependent on p53 and p73 [37] . Recent studies have demonstrated that E2F-1 upregulates the expression of the p73 gene [37, 38] . Moreover, the ectopic expression of E2F-1 does not induce apoptosis in cells derived from the p53 and p73 double-homozygous mice. Because RB can repress E2F-regulated genes, these results link RB to the inhibition of p73 expression. Taken together, the current data supports the idea that RB is an upstream inhibitor of the apoptosis function of p73 (Figure 4) . T h e inhibition of apoptosis by RB is further demonstrated by the ability of RB to inhibit the nuclear c-Abl tyrosine kinase.
Nuclear c-Abl tyrosine kinase induces apoptosis
T h e c-Abl protein is a ubiquitous cytoplasmic tyrosine kinase that contains three nuclear localization signals and a nuclear export signal [39] . In proliferating cells, c-Abl can shuttle between the nucleus and the cytoplasm in a dynamic equilibrium [40] . T h e cytoplasmic c-Abl tyrosine kinase is regulated by cell adhesion through its interaction with the F-actin cytoskeleton [41, 42] . T h e nuclear c-Abl tyrosine kinase is negatively regulated by RB, which binds to the kinase domain of c-Abl to block its activity [43, 44] . T h e nuclear c-Abl tyrosine kinase is also positively regulated by the checkpoint kinase A T M , which phosphorylates c-Abl in response to ionizing radiation [45] . Interestingly, activation of the c-Abl tyrosine kinase by DNA damage is restricted in the cell cycle. T h e c-Abl kinase activity is not activated in G , / G , cells which contain activate RB [46] . Only after RB is inactivated in late G, can c-Abl tyrosine kinase be activated by DNA damage.
Because c-Abl kinase is activated at G , / S and it is further activated by DNA damage, this nuclear tyrosine kinase could either function in DNA replication or in apoptosis. Recent evidence has demonstrated that the nuclear c-Abl tyrosine kinase can induce apoptosis in response to DNA damage [47] . A downstream effector in c-Abldependent apoptosis is the p73 protein. T h e c-Abl tyrosine kinase can stabilize the p73 and activate its pro-apoptotic function . It is interesting to note that RB can inhibit E2F and c-Abl, and that E2F and c-Abl can both activate p73. T h e transcription of p73 mRNA is stimulated by E2F [37, 38] . T h e protein stability and the proapoptotic function of p73 is stimulated by c-Abl . Taken together, these results show that RB is indeed an inhibitor of p73-dependent apoptosis (Figure 4) .
T h e apoptosis-promoting function of c-Abl requires the nuclear localization of this tyrosine kinase. This has been demonstrated through the study of Bcr-Abl, which is an oncogenic tyrosine kinase that is responsible for the development of human chronic myelogenous leukaemia. T h e Philadelphia chromosome, generated by translocation of chromosomes 9 and 22 and characteristic of chronic myelogenous leukaemia, encodes the Bcr-Abl fusion protein [51] . A coiled coil at the N-terminus of Bcr mediates the oligomerization of the Bcr-Abl protein, leading to the activation of Abl tyrosine kinase activity [52] . T h e Bcr-Abl protein contains the nuclear localization and the nuclear export signals of c-Abl. However, Bcr-Abl is retained in the cytoplasm and cannot be imported into the nucleus [53] . T h e exclusively cytoplasmic Bcr-Abl tyrosine kinase activates a number of signalling pathways to promote cell proliferation and to inhibit apoptosis [54] . Interestingly however, when Bcr-Abl is trapped in the nucleus, it activates apoptosis [53] .
T h e induction of apoptosis by the nuclear Bcr-Abl requires its tyrosine kinase activity [53] . Nuclear Bcr-Abl can activate apoptosis in p53-deficient cells, suggesting that p53 is not required for the activated c-Abl tyrosine kinase to kill cells. However, the apoptosis induced by the nuclear Bcr-Abl is p73-dependent. Expression of a dominant negative p73 protein can inhibit apoptosis induced by the nuclear Bcr-Abl tyrosine kinase (P. Vigneri and J. Y. J. Wang, unpublished work) .
T h e CrmA protein, which inhibits the death effector caspases, can also block the Bcr-Ablinduced apoptosis. Taken together, these results suggest that activation of the nuclear c-Abl tyrosine kinase can induce apoptosis through p73 and caspases. T h e mechanism of caspase activation by c-Abl and p73 remains to be determined.
Activation of p73 by DNA damage is cell cycle-dependent
T h e p73 gene is a member of the p53 family of genes, which includes p53, p63 and p73 [55-571. T h e mammalian p73 gene encodes several proteins through alternative splicing at the 5'-and the 3'-regions [55, 56] . All of the alternatively spliced p73 isoforms identified thus far contain a common DNA binding domain and a tetramerization domain [55, 56] . T h e DNA-binding domains of p73 and p53 are 66",, identical, thus, p73 can bind to the same DNA sequences as p53. Alternative splicing at S'-region of p73 leads to the expression of p73 proteins with or without an N-terminal transactivating domain (TA) [58, 59] . TA-positive p73 proteins can upregulate the expression of p53-responsive genes. Thus, TA-positive p73 proteins can induce apoptosis [60] . TA-negative p73 proteins, on the other hand, can block the expression of p53-responsive genes. Therefore, the TAnegative p73 proteins can inhibit apoptosis [59] . TA-negative p73 proteins are expressed in adult neurons where they appear to be required for the survival response to nerve growth factor [59] . By contrast, the TA-positive p73 proteins are upregulated by DNA damage in carcinoma cells to induce apoptosis [48] . Splenic T-cells isolated from p73-deficient mice are resistant to apoptosis induced by the ligation of the T-cell antigen receptors, suggesting that p73 can also induce apoptosis in activated lymphocytes [61] .
T h e pro-apoptotic function of p73 is negatively regulated by RB at two levels. First, transcription of the TA-positive p73 mRNA is activated by E2F [37.38] . T h e ectopic expression of E2F-1 has been shown to induce the expression of TA-positive p73 mRNA. In addition, E2F-1 cannot induce apoptosis in cells that are deficient for both p53 and p73 [37] . Because RB inhibits E2F-1, RB is a negative regulator of the transcription of the TA-positive p73. Secondly, the c-Abl tyrosine kinase can stabilize the p73 protein [48] . In addition, p73 cannot induce apoptosis in cells that are deficient in c-Abl, but apoptosis can be restored through the reexpression of c-Abl [48, 49] . Because RB inhibits c-Abl tyrosine kinase, RB is a negative regulator of the p73 protein function (Figure 4 ). T h e negative regulation of p73 by RB is consistent with the inhibition of apoptosis by RB.
T h e inhibition of E2F-1 and c-Abl by RB is cell cycle-regulated. When RB becomes phosphorylated at G,/S transition, E2F-1 and c-Abl are released from RB [16, 44] . Consequently, the expression of p73 is cell cycle-regulated also [37] . T h e p73 mRNA level is low in quiescent cells and it is increased as cells progress through G , / S [37] (S. W. Ki and J. Y. J. Wang, unpublished work). T h e increase in p73 mRNA is correlated with an increase in p73 protein as cells progress through G , / S . Interestingly, the p73 protein levels are further increased by genotoxic stress only after the progression through G,/S. Exposure of quiescent or early G, cells to DNA damage inducers did not induce p73 (S. W. Ki and J. Y. J. Wang, unpublished work). By contrast, the induction of p53 by genotoxic stress is cell cycle-independent.
Under conditions when genotoxic stress causes G I arrest, no induction of p73 was observed. Thus, the accumulation of p73 protein only occurs when damaged cells are blocked in S-or G,-phases of the cell cycle, e.g. through the action of hydroxyurea or etoposide. T h e cell cycle-dependent induction of p73 might account for the increased sensitivity of proliferative cells to DNA damageinduced apoptosis.
Summary and future prospects
Taken together, the current literature and unpublished results support the idea that RB plays a pivotal role in the choice between growth arrest and apoptosis. During muscle differentiation, RB is upregulated to establish terminal growth arrest with long-term survival. During genotoxic stress, the RB protein is activated to establish terminal growth arrest with long-term survival. T h e ability of RB to promote cell survival can be attributed to the ability of RB to inhibit the apoptosis function of c-Abl and p73. Thus, activation of the c-Abl and p73 pathway may complement the activation of p53 to drive apoptosis of damaged cells.
At present, we do not know why the phosphorylation of RB and the induction of p73 at each G,/S transition do not activate apoptosis. Clearly, an anti-apoptosis mechanism must accompany the phosphorylation of RB during G,/S progression to prevent cell death. Genotoxic stress may override this anti-apoptosis mechanism to allow the further accumulation of p73 and the induction of apoptosis. By studying how genotoxic stress activates the apoptosis function of p73, we should gain insights into the mechanism that suppresses apoptosis during G,/S transition.
At present, we also do not know if p53 and p73 have redundant or parallel function in the induction of apoptosis. T h e current evidence suggests that p53 and p73 can stimulate the expression of similar genes, thus indicating that they have redundant functions. However, p73 contains several alternatively spliced C-terminal regions that are not found in the p53 protein. Therefore, it is conceivable that p73 can function co-operatively with p53 to activate apoptosis. By comparing the transcription functions of p53 and p73, we may gain insights into the control of apoptosis by the p53 family of transcription factors. 
